Eupraxia Pharmaceuticals Inc. has announced a significant milestone in its clinical research. The company has reached its enrollment target of 120 patients for the Phase 2b RESOLVE trial, which is investigating EP-104GI as a treatment for Eosinophilic Esophagitis (EoE). This achievement is crucial as it marks a step forward in the development of a potential new therapy for a condition that currently has limited treatment options.

On October 15, 2026, Eupraxia issued a press release detailing this accomplishment. Dr. James Helliwell, CEO of Eupraxia, emphasized the importance of this milestone, stating, "This is a significant milestone for the RESOLVE trial and the development of EP-104GI as a potential treatment option in EoE." The company looks forward to the interim analysis scheduled for December 2026, which will provide insights into the drug's efficacy and safety.

Background

Eupraxia Pharmaceuticals Inc., incorporated in Canada, is a clinical-stage biotechnology company focused on developing innovative drug delivery systems. It operates under the SIC classification of 2834, which pertains to Pharmaceutical Preparations. The company is publicly traded on the Nasdaq under the ticker EPRX. Recent filings include multiple 6-K forms, with the most recent one filed on October 15, 2026.

What the Filing Says

The filing indicates that Eupraxia has completed the enrollment of 120 patients in the Phase 2b portion of the RESOLVE trial. The trial is designed to evaluate the safety and efficacy of EP-104GI through a placebo-controlled, blinded study. The press release highlights that over 3,000 injections of EP-104GI or a vehicle control have been administered without any treatment-related Serious Adverse Events (SAEs).

Impact

This development may significantly affect patients suffering from EoE, a condition characterized by inflammation in the esophagus that can lead to severe swallowing difficulties. The successful enrollment and ongoing safety reviews suggest that EP-104GI could become a viable treatment option if the trial results are favorable. Additionally, the pharmaceutical industry may take note of Eupraxia's progress, as it could influence competitive dynamics within the sector.

What's Next

The interim analysis of the Phase 2b portion of the RESOLVE trial is expected in December 2026. This analysis will provide critical data on the treatment's effectiveness and safety, shaping the future development of EP-104GI.

Source: SEC Accession Number 0001171843-26-006648